title: No cardiac toxicity associated with alemtuzumab therapy for mycosis fungoides/Sézary syndrome.
authors.forename: Jeanette
authors.initials: J
authors.lastname: Lundin
authors.forename: Ben
authors.initials: B
authors.lastname: Kennedy
authors.forename: Claire
authors.initials: C
authors.lastname: Dearden
authors.forename: Martin J S
authors.initials: MJ
authors.lastname: Dyer
authors.forename: Anders
authors.initials: A
authors.lastname: Osterborg
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000276:immunology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000009:adverse effects* / Q000276:immunology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005260:Female; D006321:Heart / Q000187:drug effects; D006801:Humans; D007167:Immunotherapy; D008297:Male; D008875:Middle Aged; D009182:Mycosis Fungoides / Q000188:drug therapy* / Q000276:immunology; D012189:Retrospective Studies; D012751:Sezary Syndrome / Q000188:drug therapy* / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000074323:Alemtuzumab